RMSF is the most severe spotted fever rickettsiosis, caused by Rickettsia rickettsii, an obligate intracellular bacterium transmitted by infected ticks. It carries a case-fatality rate of 20–40% when treatment is delayed, making early empiric doxycycline the single most important intervention. [1-2] The classic triad of fever, rash, and tick bite is present in only a minority at initial presentation — do not wait for the triad to treat. [1]
1. History
- Tick exposure: Outdoor activities (hiking, camping, yard work), wooded/grassy/shrubby areas; ~50% of patients do not recall a tick bite [3]
- Season: April–September peak (spring/summer), though cases occur year-round in endemic areas [3]
- Geography: Throughout the US; 60% of cases from NC, OK, AR, TN, MO; also North/South America [4]
- Incubation: 3–12 days after tick bite; shorter incubation (≤5 days) associated with more severe disease [1]
- Symptom characterization: Sudden onset high fever (>38.9°C), severe headache, chills, malaise, myalgia [1]
- Associated symptoms: Nausea, vomiting, abdominal pain, anorexia, photophobia [1]
- Rash timing: Appears 2–4 days after fever onset; starts as blanching pink macules on wrists/ankles → spreads centripetally to palms, soles, trunk [1][5]
- Important negatives: Absence of eschar (eschars are rare in RMSF, unlike other spotted fever rickettsioses); absence of erythema migrans (Lyme); absence of relapsing fevers (relapsing fever borreliosis) [2]
2. Alarm Features
- Petechial rash (especially after day 5–6) — signifies advanced, severe disease [1][4]
- Altered mental status, coma, seizures — CNS involvement [1][4]
- Pulmonary edema / ARDS [4]
- Shock / hemodynamic instability [2][6]
- Cutaneous necrosis / gangrene — may require amputation [1]
- Acute renal failure [1]
- DIC (rare but ominous) [1]
- Delay in treatment >5 days — case-fatality rates of 40–50% when treated on days 8–9 [1]
- G6PD deficiency — risk factor for fulminant RMSF with death in ≤5 days [1]
3. Medications
- First-line (all ages, including children <8 and pregnant patients): Doxycycline [1][7]
- Adults: 100 mg PO/IV BID
- Children <45 kg: 2.2 mg/kg PO/IV BID
- Duration: At least 3 days after fever resolves and clinical improvement, minimum 5–7 days total [1]
- No evidence of dental staining in children <8 at recommended dose/duration [2][7]
- IV doxycycline for patients who are vomiting, obtunded, or severely ill [1]
- Chloramphenicol: Alternative only for true doxycycline allergy/intolerance; associated with higher case-fatality rate — consult ID [2]
- CONTRAINDICATED: Sulfonamides — can worsen disease severity and increase mortality [1]
- No role for prophylactic antibiotics after tick bite in asymptomatic patients [8]
4. Diet
- No specific dietary triggers or restrictions
- Hydration: Aggressive IV fluid resuscitation may be needed in severe cases with vascular leak, but judicious fluid management is critical given risk of pulmonary edema/ARDS [4]
- Oral intake as tolerated; antiemetics for nausea/vomiting to facilitate oral doxycycline absorption
5. Review of Systems
- Constitutional: Fever, chills, malaise, fatigue, anorexia
- Neurologic: Headache (severe), photophobia, confusion, AMS, seizures, focal deficits, hearing loss [1]
- Dermatologic: Rash distribution and progression (wrists/ankles → palms/soles → trunk), petechiae
- GI: Nausea, vomiting, abdominal pain, diarrhea (GI symptoms can dominate early and mislead) [1]
- Musculoskeletal: Myalgia, arthralgia
- Pulmonary: Dyspnea, cough (pulmonary edema/ARDS)
- Renal: Decreased urine output
- Ophthalmologic: Periorbital edema, conjunctival injection [4]
6. Collateral History and Family History
- Collateral: Travel history, outdoor exposure, pet ownership (dogs carry ticks), occupational exposure, recent camping/hiking, known tick-endemic area
- Household contacts: Other family members with similar symptoms (shared tick exposure)
- Family history: G6PD deficiency — critical to identify as it predisposes to fulminant disease [1]
- Social context: Access to healthcare, ability to take oral medications, housing conditions (proximity to tick habitats)
7. Risk Factors
- Epidemiologic: Residence in or travel to endemic areas (South Central US), spring/summer season, outdoor activities [3-4]
- Age: ≥40 years and <10 years — higher mortality [1]
- Alcohol abuse [1]
- G6PD deficiency — fulminant course [1]
- Delayed treatment >5 days — the single most important modifiable risk factor for death [1]
- Immunocompromised status
- Lack of tick bite recall — paradoxically associated with increased mortality (delays diagnosis) [1]
- Disease early or late in tick season — associated with increased fatality (lower clinical suspicion) [1]
8. Differential Diagnosis
The differential for fever and rash is broad, and early RMSF is frequently misdiagnosed as a viral illness: [1][5]
- Meningococcemia — Cannot-miss; petechial/purpuric rash, rapid hemodynamic collapse; treat empirically alongside doxycycline if suspected [1]
- Ehrlichiosis / Anaplasmosis — Similar tick-borne presentation; rash less common (~30% ehrlichiosis); leukopenia more prominent; also treated with doxycycline [9-10]
- Measles — Cephalocaudal rash spread, Koplik spots, cough/coryza/conjunctivitis
- Secondary syphilis — Palms/soles rash; painless, non-pruritic; sexual history
- Viral exanthems (enterovirus, EBV, parvovirus) — Usually milder, self-limited
- Kawasaki disease (pediatric) — Conjunctival injection, mucositis, extremity changes; RMSF vasculitis can mimic [1]
- TTP/HUS — Thrombocytopenia, renal failure, neurologic changes; RMSF has been confused with TTP [1]
- Endocarditis — Petechiae, fever, new murmur
- Drug reaction — Temporal relationship to new medication
- Lyme disease — Erythema migrans (target lesion), different rash morphology [8]
- Toxic shock syndrome — Diffuse erythroderma, hypotension, desquamation
9. Past Medical History
- G6PD deficiency — fulminant disease risk [1]
- Prior tick-borne illness (does not confer reliable immunity)
- Immunosuppression (transplant, HIV, chemotherapy)
- Chronic liver or kidney disease (impacts severity and drug metabolism)
- Alcohol use disorder [1]
- Splenectomy (increased susceptibility to intracellular organisms)
- Prior antibiotic allergies (especially tetracycline class)
10. Physical Exam
- Vital signs: High fever (often >39°C), tachycardia; hypotension in late/severe disease [1]
- Skin: Careful full-body exam including palms, soles, wrists, ankles
- Early: Blanching pink macules 1–5 mm, wrists/ankles/forearms [1]
- Late: Maculopapular → petechial → purpuric; face usually spared [1]
- Skin color may prevent recognition of rash — maintain high suspicion [9]
- Cutaneous necrosis/gangrene in fulminant disease [1]
- HEENT: Periorbital/facial edema, conjunctival injection, photophobia [4]
- Neurologic: Mental status assessment, meningismus, focal deficits, cranial nerve palsies [1]
- Abdominal: Tenderness (can mimic acute abdomen)
- Extremities: Edema of hands/feet (early sign) [4]
- Thorough tick search: Scalp, axillae, groin, behind ears, umbilicus
11. Lab Studies
- CBC with differential: WBC typically normal or mildly elevated with left shift; thrombocytopenia (key finding) [1]
- CMP: Hyponatremia, elevated BUN/creatinine (renal involvement) [1][4]
- Hepatic transaminases: Mildly elevated AST/ALT [1]
- CK / LDH: Elevated in later disease (diffuse tissue injury) [1]
- Coagulation studies: PT/PTT, fibrinogen, D-dimer if DIC suspected [1]
- Blood cultures: To rule out bacterial sepsis/meningococcemia (will be negative for Rickettsia)
- Urinalysis
- CSF (if meningitis suspected): Lymphocytic pleocytosis (<100 cells/µL), mildly elevated protein (100–200 mg/dL), normal glucose [1]
- Important: Lab values are often normal or near-normal early in disease — do not rely on labs to guide early treatment decisions [1]
12. Imaging
- Chest X-ray: If respiratory symptoms present; may show pulmonary edema, ARDS pattern in severe disease [4]
- CT head: If altered mental status, focal neurologic deficits, or seizures — to evaluate for cerebral edema or alternative diagnoses
- No specific imaging is diagnostic for RMSF
- Imaging is generally unnecessary in early, uncomplicated presentations
13. Special Tests
- Confirmatory testing (do NOT delay treatment for results): [1][9]
- IFA serology (gold standard for confirmation): 4× rise in IgG between acute (within 7 days) and convalescent (2–4 weeks later) paired sera [7][9]
- IgM alone is unreliable — higher false-positive rate [7]
- Sensitivity of serology reaches 94–100% after 14 days of symptoms [9]
- Early antibiotic treatment can blunt antibody response [9]
- PCR: From skin biopsy of rash lesion (maculopapule with petechiae preferred) or whole blood; blood PCR often only positive in severe/late disease [2][9]
- Immunohistochemistry (IHC): Skin biopsy; useful within first 24 hours of antibiotic therapy [9]
- Point-of-care: No rapid bedside test currently available
- Do NOT test removed ticks for infection — not recommended [8]
14. ECG
- Obtain ECG if hemodynamically unstable or signs of myocardial involvement
- Arrhythmias can occur in severe/late disease [1]
- Tachycardia is common; conduction abnormalities possible with myocarditis
- ECG is not routinely indicated in early, uncomplicated presentations
15. Assessment
- RMSF is a clinical diagnosis — treatment must be initiated on suspicion alone [1][9]
- The classic triad (fever + rash + tick bite) is present in a minority at initial presentation [1]
- ~15% of patients never develop a rash ("spotless" RMSF) [3]
- Early disease mimics viral illness, gastroenteritis, or URI — high index of suspicion required during tick season [1][5]
- Severity stratification:
- Early/mild: Fever, headache, myalgia ± early macular rash → outpatient doxycycline
- Moderate: Rash progression, lab abnormalities, GI symptoms → close follow-up or observation
- Severe: Petechial rash, AMS, organ dysfunction, shock → ICU admission [1]
- Complications: Meningoencephalitis, ARDS, renal failure, DIC, gangrene/amputation, long-term neurologic sequelae (cognitive impairment, hearing loss, paraparesis) [1]
16. Treatment Plan
Initial stabilization (ED)
- ABCs; IV access; fluid resuscitation if hypotensive (judicious — risk of pulmonary edema)
- Start doxycycline immediately upon clinical suspicion — do not wait for labs, rash, or confirmatory testing [1][7]
Dosing
- Adults: Doxycycline 100 mg PO/IV q12h [1][11]
- Children <45 kg: Doxycycline 2.2 mg/kg PO/IV q12h [1][11]
- Duration: ≥3 days after defervescence + clinical improvement; minimum 5–7 days total [1]
- Severe/complicated disease may require longer courses [1]
Supportive care
- Antiemetics (ondansetron) to facilitate oral medication
- Antipyretics
- ICU-level care for organ dysfunction, ARDS, shock
- Blood products for severe thrombocytopenia or DIC as indicated
Response to treatment: Fever typically resolves within 24–48 hours of doxycycline if started in first 4–5 days. Lack of response at 48 hours should prompt reconsideration of diagnosis. [1]
17. Disposition
Admit if: [1]
- Petechial rash / advanced disease
- Altered mental status
- Organ dysfunction (renal failure, hepatic injury, ARDS)
- Severe thrombocytopenia
- Hemodynamic instability / need for IV pressors
- Inability to tolerate oral medications (persistent vomiting)
- Significant comorbidities or immunosuppression
- Social concerns regarding medication adherence
Discharge if
- Early disease, well-appearing, tolerating PO
- Reliable follow-up within 24–48 hours
- Able to take oral doxycycline
- Clear return precautions understood
Consult ID for: Doxycycline allergy, pregnancy, fulminant disease, diagnostic uncertainty [2][7]
18. Follow Up / Return Precautions
- Follow-up: Within 24–48 hours for all discharged patients to reassess clinical response
- Expected course: Fever should resolve within 24–48 hours of starting doxycycline [1]
- Return immediately for:
- Worsening or new rash (especially petechiae/purpura)
- Confusion, severe headache, or any neurologic changes
- Persistent vomiting / inability to take medications
- Shortness of breath
- Decreased urine output
- Persistent or worsening fever >48 hours after starting doxycycline
- Patient counseling:
- Complete the full antibiotic course
- Tick prevention: DEET-based repellents, permethrin-treated clothing, daily tick checks, prompt tick removal [8]
- No reliable immunity after infection — reinfection is possible
- Long-term sequelae are possible after severe disease (neurologic deficits, hearing loss) [1]
References
1. Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis - United States. — Biggs HM, Behravesh CB, Bradley KK, et al. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2016.
2. Rickettsial Diseases. — David W. McCormick and William L. Nicholson CDC Yellow Book. 2025.
3. The Evaluation and Management of Rocky Mountain Spotted Fever in the Emergency Department: A Review of the Literature. — Gottlieb M, Long B, Koyfman A. The Journal of Emergency Medicine. 2018.
4. Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Management of Tick-Borne Illness in the United States. — Ho BM, Davis HE, Forrester JD, et al. Wilderness & Environmental Medicine. 2021.
5. Acral manifestations associated with infection. — Jordens Q, De Maeseneer H, De Crem C, Fölster-Holst R, Van Gysel D. Pediatric Dermatology. 2021.
6. Epidemiologic Characterization and Risk Factors of Rocky Mountain Spotted Fever in Children in Northeastern Mexico: A Retrospective Cross-Sectional Study (2018-2024). — Bejarano JIC, González ÉAL, González SPC, et al. Archives of Medical Research. 2026.
7. Tickborne Diseases of the United States: A Reference Manual for Healthcare Providers Sixth Edition. — Nancy Shadick MD MPH, Nancy Maher MPH, Dennis Hoak MD United States Centers for Disease Control and Prevention (2022). 2022.
8. Tickborne Diseases: Diagnosis and Management. — Pace EJ, O'Reilly M. American Family Physician. 2020.
9. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
10. Fever of Unknown Origin. — Haidar G, Singh N. The New England Journal of Medicine. 2022.
11. FDA Drug Label. — Updated date: 2025-07-25. Food and Drug Administration.